Aeglea BioTherapeutics (AGLE) Reports Q4; Provides Program Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/9/2026
- Wall St set for higher open as chips extend gains, Middle East tensions ease
- Oil falls as investors await clarity after Iran-Israel halt attacks
- Micron to deliver 'another strong quarter', Goldman says
- Potential implications from SpaceX IPO for Tesla?
- TSMC falls as Taiwan mulls curbs on AI chip exports to China
- Hut 8 Mining Corp. (HUT) PT Raised to $55 at KBW As Management Delivers
- UK's Ofcom requires tech firms to create crisis response plans
- Exclusive-SpaceX plans to set IPO price at $135 per share, targeting record $75 billion raise, source says
- Salesforce to acquire metering platform M3TER for consumption billing
- Quantum Space to go public via $1.2B SPAC merger
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Program Updates
March 8, 2022 7:01 AM ESTAUSTIN, Texas, March 8, 2022 /PRNewswire/ --Â Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the fourth quarter and full year 2021, and provided program updates.
"2021 moved us closer to our goal of delivering life-changing medicines to people with rare metabolic diseases with positive topline data from our pivotal Phase 3 trial of pegzilarginase for Arginase 1 Deficiency and the dosing of the first patients in our Phase 1/2 trial of AGLE-177 for Homocystinuria. We... More
